US Congress confirms new drug patent listing law
22-12-2020
FDA to alter biosimilar ‘suffix’ policy
08-03-2019
FDA releases plan to boost biosimilars development
13-12-2018
Jarretera / Shutterstock.com
The Food and Drug Administration (FDA) has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Food and Drug Administration, FDA, Ned Sharpless, biologics, biosimilar, biosimilar action plan, competition
